Study of cardiovascular disease biomarkers among tobacco consumers, part 1: Biomarkers of exposure

Inhalation Toxicology

Volumn 27, Issue 3, 2015, Pages 149-156

  Campbell, Leanne R ^a   Brown, Buddy G ^a   Jones, Bobbette A ^a   Marano, Kristin M ^b   Borgerding, Michael F ^a  

^a R J REYNOLDS TOBACCO COMPANY   (United States)

^b RAI Innovations Company   (United States)

Author keywords

Cigarettes; Clinical study; CVD; Harmful and potentially harmful constituents; Moist snuff; Spot urines

Indexed keywords

1,3 BUTADIENE; ACROLEIN; ACRYLAMIDE; AROMATIC AMINE; BENZENE; BIOLOGICAL MARKER; CARBON MONOXIDE; CROTONALDEHYDE; PYRENE; TOBACCO SMOKE;

ADULT; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIZZINESS; EXPOSURE; FAGERSTROM TEST FOR NICOTINE DEPENDENCE; HEADACHE; HUMAN; MALE; PRIORITY JOURNAL; SMOKELESS TOBACCO; SMOKING; TOBACCO; URINALYSIS; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; CROSS-SECTIONAL STUDY; MIDDLE AGED; RISK FACTOR; TOBACCO DEPENDENCE;

NICOTIANA TABACUM;

ADULT; BIOMARKERS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SMOKING; TOBACCO USE DISORDER;

EID: 84929415448     PISSN: 08958378     EISSN: 10917691     Source Type: Journal    
DOI: 10.3109/08958378.2015.1013228     Document Type: Article

References (40)

1. Adhikari B, Kahende J, Malarcher A, et al. (2008). Smoking-Attributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004. MMWR 57: 1226-8
2. Benowitz, NL. (2003). Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 46: 91-111
3. Byrd GD, Ogden MW. (2003). Liquid chromatographic/tandem mass spectrometric method for the determination of the tobacco-specific nitrosamine metabolite NNAL in smokers' urine. J Mass Spectrom 38: 98-107
4. Calapai G, Caputi AP, Mannucci C, et al. (2009). A cross-sectional investigation of biomarkers of risk after a decade of smoking. Inhal Toxicol 21: 1138-43
5. Federal Trade Commission (FT). (2008). FTC rescinds guidance from 1966 on statements concerning tar and nicotine yields. Available from: http://www.ftc.gov/opa/2008/11/cigarettetesting.shtm. [Last accessed: 7 Nov 2012]
6. Food and Drug Administration (FD). (2012). Guidance for industry: reporting harmful and potentially harmful constituents in tobacco products and tobacco smoke under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act. Draft guidance. Available from: http://www.fda.gov/downloads/TobaccoProducts/GuidanceCompliance RegulatoryInformation/UCM297828.pdf [Last accessed: 25 Mar 2014]
7. Gillespie CD, Wigington C, Hong Y. (2013). Coronary heart disease and stroke deaths-United States, 2009. MMWR 62: 157-60
8. Gregg EQ, Minet E, McEwan M. (2013). Urinary biomarkers of smokers' exposure to tobacco smoke constituents in tobacco products assessment: a fit for purpose approach. Biomarkers 18: 467-86
9. Hansson J, Galanti MR, Hergens MP, et al. (2012). Use of snus and acute myocardial infarction: pooled analysis of eight prospective observational studies. Eur J Epidemiol 27: 771-9
10. Hansson J, Galanti MR, Hergens MP, et al. (2014). Snus (Swedish smokeless tobacco) use and risk of stroke: pooled analyses of incidence and survival. J Int Med 276: 87-95
11. Hatsukami DK, Benowitz NL, Rennard SI, et al. (2006). Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res 8: 600-22
12. Heavner DL, Morgan WT, Sears SB, et al. (2006). Effect of creatinine and specific gravity normalization techniques on xenobiotic biomarkers in smokers' spot and 24-h urines. J Pharm Biomed Anal 40: 928-42
13. Hecht SS, Carmella SG, Edmonds A, et al. (2008). Exposure to nicotine and a tobacco-specific carcinogen increase with duration of use of smokeless tobacco. Tob Control 17: 128-31
14. Hecht SS, Carmella SG, Murphy SE, et al. (2007). Similar exposure to a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers. Cancer Epidemiol Biomarkers Prev 16: 1567-72
15. Henley SJ, Connell CJ, Richter P, et al. (2007). Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tob Control 16: 22-8
16. Henley SJ, Thun MJ, Connell C, Calle EE. (2005). Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control 16: 347-58
17. Heudorf U, Angerer J. (2001). Urinary monohydroxylated phenanthrenes and hydroxypyrene-The effects of smoking habits and changes induced by smoking on monooxygenase-mediated metabolism. Int Arch Occup Environ Health 74: 177-83
18. Institute of Medicine (IOM). (2011). Scientific standards for studies on modified risk tobacco products. Washington, DC: The National Academies Press
19. International Agency for Research on Cancer (IAR). (2007). Smokeless tobacco and some tobacco-specific N-nitrosamines. IARC monographs on the evaluation of carcinogenic risks to humans, volume 89. Lyon, France: World Health Organization
20. Jilma B, Dirnberger E, Löscher I, et al. (1997). Menstrual cycleassociated changes in blood levels of interleukin-6, alpha1 acid glycoprotein, and C-reactive protein. J Lab Clin Med 130: 69-75
21. Lee PN, Hamling J. (2009). Systematic review of the relation between smokeless tobacco and cancer in Europe and North America. BMC Med 7: 36
22. Lowe FJ, Gregg EO, McEwan M. (2009). Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and neversmokers. Clin Chem Lab Med 47: 311-20
23. Marano KM, Kathman SJ, Jones BA, et al. (2015). Study of cardiovascular disease biomarkers among tobacco consumers, part 3: evaluation and comparison with the US National Health and Nutrition Examination Survey. Inhal Toxicol. (in press
24. Meger M, Meger-Kossien I, Schuler-Metz A, et al. (2002). Simultaneous determination of nicotine and eight nicotine metabolites in urine of smokers using liquid chromatography-Tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 778: 251-61
25. Messner B, Bernhard D. (2014). Smoking and cardiovascular disease mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 34: 509-15
26. Nan HM, Kim H, Lim HS, et al. (2001). Effects of occupation, lifestyle and genetic polymorphisms of CYP1A1, CYP2E1, GSTM1 and GSTT1 on urinary 1-hydroxypyrene and 2-naphthol concentrations. Carcinogenesis 22: 787-93
27. Naufal ZS, Marano KM, Kathman SJ, Wilson CL. (2011). Differential exposure biomarker levels among cigarette smokers and smokeless tobacco consumers in the National Health and Nutrition Examination Survey 1999-2008. Biomarkers 16: 222-35
28. Nordskog BK, Brown BG, Marano KM, et al. (2015). Study of cardiovascular disease biomarkers among tobacco consumers, part 2: biomarkers of biological effect. Inhal Toxicol. (in press
29. Nutt DJ, Phillips LD, Balfour D, et al. (2014). Estimating the harms of nicotine-containing products using the MCDA approach. Eur Addict Res 20: 218-25
30. Piano MR, Benowitz NL, Fitzgerald GA, et al. (2010). Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association. Circulation 122: 1520-44
31. Roethig HJ, Munjal S, Feng S, et al. (2009). Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers. Nicotine Tob Res 11: 1216-25
32. Scherer G. (2005). Biomonitoring of inhaled complex mixtures-Ambient air, diesel exhaust and cigarette smoke. Exp Toxicol Pathol 57(Suppl. 1): 75-110
33. Stepanov I, Hecht SS. (2005). Tobacco-specific nitrosamines and their pyridine-N-glucuronides in the urine of smokers and smokeless tobacco users. Cancer Epidemiol Biomarkers Prev 14: 885-91
34. Stratton K, Shetty P, Wallace R, Bondurant S. (2001). Clearing the smoke: the science base for tobacco harm reduction-executive summary. Tob Control 10: 189-95
35. Thun MJ, Apicella LF, Henley SJ. (2000). Smoking vs other risk factors as the cause of smoking-Attributable deaths: confounding in the courtroom. J Am Med Assoc 284: 706-12
36. US Department of Health and Human Services. (USDHHS). (2004). The health consequences of smoking: a report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health
37. US Department of Health and Human Services. (USDHHS). (2010). How tobacco smoke causes disease: the biology and behavioral basis for smoking-Attributable disease: a report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health
38. Vesper HW, Caudill SP, Osterloh JD, et al. (2010). Exposure of the U.S. population to acrylamide in the National Health and Nutrition Examination Survey 2003-2004. Environ Health Perspect 118: 278-83
39. World Health Organization (WHO). (2013). Cardiovascular diseases (CVDs), Fact Sheet No. 317. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/. [Last accessed: 27 Mar 2014]
40. Zeller M, Hatsukami D, Strategic Dialogue on Tobacco Harm Reduction Group. (2009). The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US. Tob Control 18: 324-32